This Experimental Hematology & Oncology series on 'New developments in CAR T, CAR NK, and CAR macrophage cell therapies' is open. CAR engineered cell therapies are moving rapidly from bench to bedside. This collection welcomes studies covering the latest development in pre-clinical and clinical studies of CAR -engineered cell therapies. Submissions can be made via the journal's submission system. For more information, visit the full collection webpage.
Call for papers: New developments in CAR T, CAR NK, and CAR macrophage cell therapies
Call for papers: Oncobiome
The new cross journal collection 'Oncobiome' is now open for submissions. The oncobiome encompasses the diverse microbial communities residing in and on the human body, which influence cancer development, progression, and treatment responses. By examining these interactions, our aim is to unravel the complex mechanisms through which the microbiome impacts oncogenesis and therapeutic outcomes. For more information, visit the collection webpage
Call for papers: Latest updates from major conferences
This Experimental Hematology & Oncology and Journal of Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference. Submissions can be made via the journal's submission system. For more information, visit the full collection page.
Articles
-
-
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma
-
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies
-
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
-
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
-
Breast cancer brain metastases: the last frontier
-
COVID-19 vaccination associated severe immune thrombocytopenia
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Breast Cancer Awareness Month 2024
October is breast cancer awareness month. We are standing together to raise awareness about breast cancer, a disease that affects millions of lives worldwide. Awareness and research are essential for early detection, better treatments, and ultimately saving lives. Take a look at these influential articles which aim to promote further research into breast cancer treatments and testing.
Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Editors-in-Chief
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical College
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 9.4
5-year Journal Impact Factor: 8.3
Source Normalized Impact per Paper (SNIP): 1.583
SCImago Journal Rank (SJR): 2.384Speed 2023
Submission to first editorial decision (median days): 2
Submission to acceptance (median days): 100Usage 2023
Downloads: 696,150
Altmetric mentions: 375
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-